Background: Confirmatory data on long-term effectiveness and safety of ixekizumb in psoriatic patients from real-world studies are needed. Objectives: The primary aim was to evaluate the 3-year drug survival of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis, in a multicenter real-world setting. The secondary aim was to assess the influence of predictive factors on the drug survival of ixekizumab. Methods: A retrospective analysis was performed on a cohort of patients with chronic plaque psoriasis, who received at least one dose of ixekizumab before December 2018. The drug survival analysis was performed, descriptively analyzed using Kaplan-Meier survival curves. Multivariable Cox regression analyses were carried out including variables considered of clinical importance. Results: A total of 306 patients was enrolled. The overall drug survival at 12, 24 and 36 months of treatment with ixekizumab was 92.11%, 83.85% and 80.19%, respectively. A higher probability (HR 2.34) of drug withdrawal was found among patients who had already received an anti-IL-17 agent compared with bio-naive patients (p 0.017). Conclusions: We found that ixekizumab is a biological agent characterized by a long term effectiveness, not influenced by several clinical factors and associated with a good safety profile.

Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study / Caldarola, G; Chiricozzi, A; Megna, M; Dapavo, P; Giunta, A; Burlando, M; Malagoli, P; Dini, V; Mariani, M; Fabbrocini, G; Quaglino, P; Bianchi, L; Parodi, A; Peris, K; De Simone, C. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - (2023). [10.1080/14712598.2023.2193288]

Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study

M Megna;G Fabbrocini;
2023

Abstract

Background: Confirmatory data on long-term effectiveness and safety of ixekizumb in psoriatic patients from real-world studies are needed. Objectives: The primary aim was to evaluate the 3-year drug survival of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis, in a multicenter real-world setting. The secondary aim was to assess the influence of predictive factors on the drug survival of ixekizumab. Methods: A retrospective analysis was performed on a cohort of patients with chronic plaque psoriasis, who received at least one dose of ixekizumab before December 2018. The drug survival analysis was performed, descriptively analyzed using Kaplan-Meier survival curves. Multivariable Cox regression analyses were carried out including variables considered of clinical importance. Results: A total of 306 patients was enrolled. The overall drug survival at 12, 24 and 36 months of treatment with ixekizumab was 92.11%, 83.85% and 80.19%, respectively. A higher probability (HR 2.34) of drug withdrawal was found among patients who had already received an anti-IL-17 agent compared with bio-naive patients (p 0.017). Conclusions: We found that ixekizumab is a biological agent characterized by a long term effectiveness, not influenced by several clinical factors and associated with a good safety profile.
2023
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study / Caldarola, G; Chiricozzi, A; Megna, M; Dapavo, P; Giunta, A; Burlando, M; Malagoli, P; Dini, V; Mariani, M; Fabbrocini, G; Quaglino, P; Bianchi, L; Parodi, A; Peris, K; De Simone, C. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - (2023). [10.1080/14712598.2023.2193288]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/914917
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact